Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | NMT1 | P30419 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16905987 | 0.86 | L3MBTL1 (0.46) | SCN9AHDAC1HDAC8HDAC6HDAC5 | |
| SCHEMBL20373353 | 0.86 | HDAC1 (0.40) | SCN9AHDAC1HDAC8HDAC6HDAC5 | |
| SCHEMBL20373749 | 0.86 | SCN9A (0.36) | SCN9AHDAC1HDAC8HDAC6HDAC5 | |
| SCHEMBL18326359 | 0.85 | CPT1A (0.41) | HDAC1HDAC8HDAC6HDAC5L3MBTL1 | |
| SCHEMBL16905954 | 0.85 | HDAC1 (0.40) | SCN9AHDAC1HDAC8HDAC6HDAC5 | |
| SCHEMBL18326360 | 0.85 | HDAC6 (0.42) | SCN9AHDAC1HDAC8HDAC6HDAC5 | |
| SCHEMBL16896879 | 0.84 | BRD4 (0.39) | BRD4NMT1 | |
| SCHEMBL16905984 | 0.81 | BRD4 (0.54) | SCN9AL3MBTL1BRD4 | |
| SCHEMBL18326362 | 0.76 | L3MBTL1 (0.46) | PIK3CGL3MBTL1BRD4 | |
| SCHEMBL16905973 | 0.76 | L3MBTL1 (0.46) | SCN9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590118-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | ORION CORPORATION (FI) | 2020-03-17 | — | — | US | disclosed |
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | US | disclosed |
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD1, BRD2, BRD3 | SCN9A 1742/4885HDAC1 14/4885HDAC8 479/4885 |
| US-10590118-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | BRD1, BRD2, BRD3 | SCN9A 1742/4885HDAC1 14/4885HDAC8 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.